Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-6356 DDI with Midazolam, Caffeine, or Rosuvastatin
NCT03970798Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sipagladenant in Parkinson's disease (PD), sponsored by Kyowa Kirin. Primary endpoint: Area Under the Curve from time zero to last quantifiable concentration at Day 11. Started May 2019; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03970798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970798.